Immunomedics +18.5% AH on start of pancreatic cancer drug phase-3 trial

|By:, SA News Editor

Immunomedics (IMMU) +18.5% AH after announcing it began treating patients with its 90Y-clivatuzumab tetraxetan pancreatic cancer drug in a late-stage clinical trial.

The phase-3 trial is a double-blind, randomized study aimed to evaluate the safety and efficacy of the drug combined with low-dose gemcitabine and best supportive care in patients with metastatic pancreatic cancer who have received at least two prior therapies.